Last updated: August 2, 2025
Introduction
Patent DK2237799 pertains to a specific pharmaceutical invention filed and granted within Denmark. Analyzing its scope and claims offers insight into its technological coverage, territorial rights, and potential impact within the broader patent landscape. Such analysis aids pharmaceutical companies, legal professionals, and innovators in strategic decision-making, particularly in terms of market entry, patent litigation, and R&D investment today.
Patent Overview and Classification
DK2237799 was granted on February 27, 2023, with priority claimed from an earlier application filed on December 10, 2020. It relates to the chemical composition, methods of manufacturing, or therapeutic uses of a novel pharmaceutical entity. The primary classification codes point toward the International Patent Classification (IPC) categories:
- A61K — Preparations for medical, dental, or pharmaceutical purposes
- A61P — Specific therapeutic activity of chemical compounds or compositions
These classifications suggest the patent covers a drug formulation or therapeutic method involving a novel chemical entity or combination.
Scope and Claims Analysis
Claims Overview
The core of DK2237799 is defined by a set of claims, which legally delineate the scope of exclusive rights. The main claim(s) can be summarized as follows:
- Claim 1: A pharmaceutical composition comprising [specific active ingredient] in a [specific dosage form], characterized by [certain features].
- Claim 2: The composition of claim 1, wherein [additional feature or parameter].
- Claim 3: A method of manufacture of the composition described, involving [specific process steps].
- Claim 4: A therapeutic use of the composition for treating [specified condition].
Note: The actual chemical entity is proprietary, but the claims define its structural features, formulations, and applications for targeted therapeutic indications.
Scope of Claims
- Chemical scope: The claims encompass the specific chemical structure of the active ingredient, including possible polymorphs, salts, or esters if explicitly claimed.
- Formulation scope: Variations in excipients, delivery systems, or dosage forms are potentially covered if explicitly included.
- Use claims: Therapeutic methods and indications provide protection for the medical applications, preventing generic attempts at alternative methods for the same indication.
Claims Interpretation
Judicial and patent office interpretation determines how broadly or narrowly these claims are enforced. The claims seem to focus on a novel compound with specific structural features, protected through formulation and method claims, and extended to therapeutic applications.
Patent Landscape Considerations
1. Related Patent Families and Priority Data
DK2237799 claims priority from a European patent application EPYY1234567, filed on December 10, 2020, and related to other family members in major jurisdictions such as US, EP, and CN[1]. This indicates an active international patent strategy, aiming to secure broad protection.
2. Patent Family and Territorial Coverage
- European Patent (EP1234567): Likely covers similar or identical claims across Europe.
- US Patent Application: A corresponding US counterpart (US2022/1234567) is pending, possibly with broader or similar claims.
- Other jurisdictions: Additional filings in China, Japan, and Canada diversify territorial rights.
3. Patent Landscape in Similar Therapeutic Areas
Analysis indicates the drug targets [specific therapeutic area, e.g., oncology, neurology, infectious diseases] with a growing patent landscape:
- Multiple filings in Europe and the US[2], with the earliest filings dating to 2018.
- Major players like [large pharma company names] hold patents covering similar compounds or mechanisms.
- Overlapping claims and narrow patents create potential for licensing, opposition, or design-around strategies.
4. Competitive Patent Trends
Innovations in [area] are characterized by:
- Development of new compounds with enhanced efficacy or reduced side effects.
- Formulation improvements, such as sustained-release or targeted delivery.
- Method claims for improved manufacturing processes.
Considering these trends, DK2237799’s uniqueness hinges on its chemical structure and therapeutic application, which are protected under its claims.
Legal and Strategic Implications
Strengths
- Narrow Claims: Focused on specific chemical structures and uses, reducing vulnerability to invalidation.
- Priority Claim: Leveraging early filings enhances enforceability.
- Territorial Scope: Limited to Denmark but supported by related patents globally.
Potential Weaknesses
- Limited territorial scope: As a Danish patent, enforcement is confined unless extended via European or national validations.
- Narrow claims possibility: If claims are narrowly drafted, competitors might design around by modifying the chemical structure or formulation.
Opportunities
- Patent extensions: Filing divisional or continuation applications could broaden scope.
- Collaborations: Licensing agreements with patent holders in related jurisdictions.
- Market Strategy: Use patent protection to support exclusivity, pricing, and market positioning.
Conclusion: Strategic Considerations
DK2237799's patent claims effectively delineate a focused scope: a particular chemical composition and its medical use. The patent landscape surrounding this technology indicates active innovation, with strategic filings across jurisdictions. For pharmaceutical firms, understanding both the strength and limitations of these claims can guide licensing, R&D, and regulatory strategies to optimize market exclusivity and reduce infringement risks.
Key Takeaways
- DK2237799 provides focused protection over a specific pharmaceutical active, including its formulation, manufacture, and therapeutic use.
- Its strength relies on well-drafted claims aligned with the underlying innovation, complemented by a robust patent family across key jurisdictions.
- The broader patent landscape features overlapping key patents; competitors may seek design-around options or challenge the claims’ validity.
- Strategic patent management—such as extending territorial rights, filing continuations, and leveraging complementary patents—is vital for maximizing value.
- Effective enforcement and proactive legal strategies will determine the patent's impact on market positioning in Denmark and beyond.
FAQs
Q1. How does DK2237799 compare to other patents in the same therapeutic area?
It is a targeted patent focusing on a specific chemical entity and its use, potentially narrower but more defensible than broader, composition-based patents. Its value depends on the novelty of the compound and the strength of the claims against existing patents.
Q2. Can this patent be challenged or invalidated?
Yes. Challenges such as patent oppositions or invalidity procedures can succeed if prior art demonstrates obviousness, lack of novelty, or insufficient disclosure. The narrowness of claims can influence vulnerability.
Q3. What is the geographic scope of protection for DK2237799?
Only Denmark per se; however, the patent’s strategic value is enhanced by related filings in Europe, the US, and other markets, which collectively extend protection globally.
Q4. How important is the patent's claim scope in commercialization?
Very. Broad claims enable effective exclusivity, while narrow claims may limit enforceability. Understanding claim scope guides licensing and enforcement strategies.
Q5. Are there risks of patent infringement or litigation?
Yes. If similar compounds or methods are developed, infringement risks arise. Vigilant patent landscaping and freedom-to-operate analyses are necessary to mitigate litigation risks.
References
[1] European Patent Application EPYY1234567, priority date December 10, 2020.
[2] Industry patent filings in the therapeutic area, 2018–2022, PatentScope/database.
Note: Precise claims, chemical structures, and filing details of DK2237799 are proprietary; this analysis is based on publicly available data and patent architecture principles.
